Consultant Psychiatrist - Clozapine Clinic lead
Mental Health Speciality co-lead - NIHR-CRN: Eastern
As an overview of my trajectory, I’m a clinical academic with main interest in schizophrenia and psychosis. I’m employed by the Cambridge and Peterbourgh NHS Foundation Trust (CPFT) and I act as Trust’s Lead Clinician for the Clozapine Clinic. Until Feb 2015, I was also the Associate Clinical Director for the WT/MRC Behavioural and Clinical Neuroscience Institute (BCNI), University of Cambridge.
I completed my training in psychiatry in Barcelona (Spain) in 2003 and I moved to Cambridge in 2007, where I worked at the early intervention in psychosis service for 4 years. Since 2011 I lead the clozapine clinic. At the clinic, while providing excellent clinical care, we also study the processes associated to the perpetuation of chronic psychosis. We approach this model through studies in genetics, metabolism, ageing, imaging, immunology and inflammation, clinical phenomenology/cognition and epidemology and mouse models of clozapine action both in house and in collaboration with other centres. The molecular pathways that links schizophrenia and rest of the body is my main research line. My publication record shows over 25 original research papers on this topic and the entirety of my research career, over 50 original manuscripts (h-index of 15). I have also acted as peer reviewer for different journals in psychiatry and I am member of a several research societies. With regard to other merits: I have received a number of awards for my clinical work, research and PhD, and I have been recognized for publishing the best divulgative book about schizophrenia in Spanish (over 10,000 copies have been sold).
Departments and Institutes
- Visiting Researcher
My research interests are mostly the biological and clinical aspects of chronic schizophrenia. I’m the Clozapine Clinic Lead and the Good Outcome Schizophrenia Clinic lead for the local MH Trust (Cambridgeshire and Peterborough NHS Foundation Trust). We are now involved in several studies looking at subjects suffering with treatment resistant schizophrenia from different angles. These include studies on biomarkers (metabolism, immunity and inflammation), genetics, neuroimaging, clinical epidemiology, interaction between physical and mental health and clinical trials with new interventions (both pharmacological and non-pharmacological).
Fernandez-Egea E, Garcia-Rizo C, Zimbron J, Kirkpatrick B (2013), “Diabetes or prediabetes in newly diagnosed patients with nonaffective psychosis? A historical and contemporary view.” Schizophr Bull 39(2):266-7 Details
Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, Kirkpatrick B (2009), “Metabolic profile of antipsychotic-naive individuals with non-affective psychosis.” Br J Psychiatry 194(5):434-8 Details
Fernandez-Egea E, Bernardo M, Heaphy CM, Griffith JK, Parellada E, Esmatjes E, Conget I, Nguyen L, George V, Stöppler H, Kirkpatrick B (2009), “Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis.” Schizophr Bull 35(2):437-42 Details
Fernandez-Egea E, Bruna A, Garcia-Rizo C, Bernardo M, Kirkpatrick B (2009), “Stem cell signaling in newly diagnosed, antipsychotic-naive subjects with nonaffective psychosis.” Mol Psychiatry 14(11):989-91 Details